Morphogens

Cerapedics Announces Commercial Launch of i-FACTOR®+ Matrix in Canada

Retrieved on: 
Thursday, November 5, 2020
Branches of biology, Cell biology, Growth factors, Proteins, Biology, Epidermal growth factor, Morphogens, Collagen, Peptide, Lumican, NOV, Biomaterials

WESTMINSTER, Colo., Nov. 5, 2020 /PRNewswire/ --Cerapedics, a private ortho-biologics company, today announced the full commercial availability of i-FACTOR+ MATRIX for surgical implantation in Canada.

Key Points: 
  • WESTMINSTER, Colo., Nov. 5, 2020 /PRNewswire/ --Cerapedics, a private ortho-biologics company, today announced the full commercial availability of i-FACTOR+ MATRIX for surgical implantation in Canada.
  • "Canada will be the first market offering the i-FACTOR+ MATRIX product, which leverages the clinically proven P-15 osteogenic cell-binding peptide combined with a collagen carrier for optimized handling."
  • i-FACTOR+ MATRIX utilizes a small proprietary peptide (P-15) technology developed by Cerapedics to support bone growth through cell attraction, attachment, and activation.
  • "In addition to the commercial launch in Canada, the latest i-FACTOR+ MATRIX generation is currently being studied in our FDA IDE study, ASPIRE, targeting lumbar fusions (TLIF), as previously announced.

Kanazawa University research: Engineering biological pattern formation with synthetic morphogens

Retrieved on: 
Thursday, November 5, 2020
Morphogens, Developmental biology, Branches of biology, Biology, Life sciences, Tissue engineering, Pattern formation, French flag model, Evolutionary developmental biology, Systems biology

KANAZAWA, Japan, Nov. 5, 2020 /PRNewswire/ --Researchers at Kanazawa University report, in Science how concentration gradients of particular molecules ('synthetic morphogens') can be produced in biological systems.

Key Points: 
  • KANAZAWA, Japan, Nov. 5, 2020 /PRNewswire/ --Researchers at Kanazawa University report, in Science how concentration gradients of particular molecules ('synthetic morphogens') can be produced in biological systems.
  • Such gradients can be exploited for programming pattern formation, offering the promise of controlled tissue engineering.
  • Now, Satoshi Toda from Kanazawa University and colleagues report the successful engineering of a synthetic morphogen system that can be programmed.This achievement not only helps to understand how exactly morphogens encode positional information, but is also promising in the context of engineered tissue formation.
  • Caption:Arbitrary proteins such as GFP can turn into a synthetic morphogen that forms a gradient pattern of gene expression.

Kanazawa University research: Engineering biological pattern formation with synthetic morphogens

Retrieved on: 
Thursday, November 5, 2020
Morphogens, Developmental biology, Branches of biology, Biology, Life sciences, Tissue engineering, Pattern formation, French flag model, Evolutionary developmental biology, Systems biology

KANAZAWA, Japan, Nov. 5, 2020 /PRNewswire/ --Researchers at Kanazawa University report, in Science how concentration gradients of particular molecules ('synthetic morphogens') can be produced in biological systems.

Key Points: 
  • KANAZAWA, Japan, Nov. 5, 2020 /PRNewswire/ --Researchers at Kanazawa University report, in Science how concentration gradients of particular molecules ('synthetic morphogens') can be produced in biological systems.
  • Such gradients can be exploited for programming pattern formation, offering the promise of controlled tissue engineering.
  • Now, Satoshi Toda from Kanazawa University and colleagues report the successful engineering of a synthetic morphogen system that can be programmed.This achievement not only helps to understand how exactly morphogens encode positional information, but is also promising in the context of engineered tissue formation.
  • Caption:Arbitrary proteins such as GFP can turn into a synthetic morphogen that forms a gradient pattern of gene expression.

Trefoil Therapeutics to Present Update on Regenerative Treatments for Corneal Diseases

Retrieved on: 
Monday, November 2, 2020
Biotechnology, Pharmaceutical, Optical, Health, Branches of biology, Fibroblast growth factor, Morphogens, FGF1, Growth factor, Biology

Trefoil Therapeutics announced today it will provide an update on the company and its clinical program for TTHX1114 at the upcoming Eyecelerator virtual conference.

Key Points: 
  • Trefoil Therapeutics announced today it will provide an update on the company and its clinical program for TTHX1114 at the upcoming Eyecelerator virtual conference.
  • TTHX1114 is the companys first-in-class, engineered fibroblast growth factor 1 (FGF-1), for the regenerative treatment of corneal diseases.
  • Trefoil also has a topical product based on its engineered FGF-1 that is in preclinical development for the treatment of corneal epithelial disorders.
  • Trefoil Therapeutics is a private biotechnology company focused on leveraging its engineered fibroblast growth factor-1 protein technology platform to develop first-in-class pharmacologic treatments for serious corneal endothelial diseases and epithelial disorders.

Press release - Parliament backs €1.6 million to help former workers of Carrefour Belgium

Retrieved on: 
Thursday, November 14, 2019
Economy of the European Union, European Globalisation Adjustment Fund, Growth factors, EGF, Morphogens, Jos, Epidermal growth factor

The total estimated funding amounts to 2.7 million, of which the EGF would provide 60% (1.6 million).

Key Points: 
  • The total estimated funding amounts to 2.7 million, of which the EGF would provide 60% (1.6 million).
  • The draft report by Jos Manuel Fernandes (EPP, PT), recommending that Parliament approve the aid, was passed by 558 votes to 63, and 43 abstentions.
  • Background

    The European Globalisation Adjustment Fund (EGF) contributes to packages of tailor-made services to help redundant workers find new jobs.

  • According to the Belgian Federation for Commerce and Services, 67% of Belgian consumers shopped online in 2018 - up from 46% in 2012.

Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors - Pipeline Insights, 2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 8, 2019
Health, Pharmaceutical, Branches of biology, Tyrosine kinase receptors, Cell biology, Growth factors, Biology, Fibroblast growth factor, Morphogens, Trafermin, Fibroblast growth factor receptor 1

The "Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors - Pipeline Insights, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors - Pipeline Insights, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors development.
  • clinical, pre-clinical and discovery stages for Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors
    The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
    Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors
    Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
    2.
  • Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors -Pipeline Insights, 2019 Overview
    An Overview of Pipeline Products for Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors -Pipeline Insights, 2019

Limoneira Enters Agreement to Expand Global Presence with Strategic Joint Venture and Land Acquisition in Argentina

Retrieved on: 
Monday, February 4, 2019
Natural Resources, Agriculture, Retail, Food, Beverage, Countries, Branches of biology, Growth factors, Fibroblast growth factor, Morphogens, Forward-looking statement, Argentina, International organizations

As part of the agreement, Limoneira will create a subsidiary in Argentina under the name Limoneira Argentina S.A.U.

Key Points: 
  • As part of the agreement, Limoneira will create a subsidiary in Argentina under the name Limoneira Argentina S.A.U.
  • Limoneira Argentina and FGFs agreement will operate under the name Trapani Fresh, with Limoneira Argentina as the managing partner and responsible for all fresh fruit sales, holding a 51% interest and FGF holding a 49% interest.
  • This joint venture fits in nicely with our One World of Citrus initiative and we are looking forward to welcoming FGFs family owned business to the Limoneira team.
  • Limoneira undertakes no obligation to subsequently update or revise the forward-looking statements made in this press release, except as required by law.